Cargando…

Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS

Increasing evidence indicates an excitatory/inhibitory imbalance may have a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Impaired inhibitory circuitry is consistently reported in the motor cortex of both familial and sporadic patients, closely associated with cortical hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Rosemary M., Blizzard, Catherine A., Young, Kaylene M., King, Anna E., Dickson, Tracey C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353592/
https://www.ncbi.nlm.nih.gov/pubmed/28294153
http://dx.doi.org/10.1038/srep44461
_version_ 1782515140664492032
author Clark, Rosemary M.
Blizzard, Catherine A.
Young, Kaylene M.
King, Anna E.
Dickson, Tracey C.
author_facet Clark, Rosemary M.
Blizzard, Catherine A.
Young, Kaylene M.
King, Anna E.
Dickson, Tracey C.
author_sort Clark, Rosemary M.
collection PubMed
description Increasing evidence indicates an excitatory/inhibitory imbalance may have a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Impaired inhibitory circuitry is consistently reported in the motor cortex of both familial and sporadic patients, closely associated with cortical hyperexcitability and ALS onset. Inhibitory network dysfunction is presumably mediated by intra-cortical inhibitory interneurons, however, the exact cell types responsible are yet to be identified. In this study we demonstrate dynamic changes in the number of calretinin- (CR) and neuropeptide Y-expressing (NPY) interneurons in the motor cortex of the familial hSOD1(G93A) ALS mouse model, suggesting their potential involvement in motor neuron circuitry defects. We show that the density of NPY-populations is significantly decreased by ~17% at symptom onset (8 weeks), and by end-stage disease (20 weeks) is significantly increased by ~30%. Conversely, the density of CR-populations is progressively reduced during later symptomatic stages (~31%) to end-stage (~36%), while CR-expressing interneurons also show alteration of neurite branching patterns at symptom onset. We conclude that a differential capacity for interneurons exists in the ALS motor cortex, which may not be a static phenomenon, but involves early dynamic changes throughout disease, implicating specific inhibitory circuitry.
format Online
Article
Text
id pubmed-5353592
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53535922017-03-20 Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS Clark, Rosemary M. Blizzard, Catherine A. Young, Kaylene M. King, Anna E. Dickson, Tracey C. Sci Rep Article Increasing evidence indicates an excitatory/inhibitory imbalance may have a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Impaired inhibitory circuitry is consistently reported in the motor cortex of both familial and sporadic patients, closely associated with cortical hyperexcitability and ALS onset. Inhibitory network dysfunction is presumably mediated by intra-cortical inhibitory interneurons, however, the exact cell types responsible are yet to be identified. In this study we demonstrate dynamic changes in the number of calretinin- (CR) and neuropeptide Y-expressing (NPY) interneurons in the motor cortex of the familial hSOD1(G93A) ALS mouse model, suggesting their potential involvement in motor neuron circuitry defects. We show that the density of NPY-populations is significantly decreased by ~17% at symptom onset (8 weeks), and by end-stage disease (20 weeks) is significantly increased by ~30%. Conversely, the density of CR-populations is progressively reduced during later symptomatic stages (~31%) to end-stage (~36%), while CR-expressing interneurons also show alteration of neurite branching patterns at symptom onset. We conclude that a differential capacity for interneurons exists in the ALS motor cortex, which may not be a static phenomenon, but involves early dynamic changes throughout disease, implicating specific inhibitory circuitry. Nature Publishing Group 2017-03-15 /pmc/articles/PMC5353592/ /pubmed/28294153 http://dx.doi.org/10.1038/srep44461 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Clark, Rosemary M.
Blizzard, Catherine A.
Young, Kaylene M.
King, Anna E.
Dickson, Tracey C.
Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title_full Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title_fullStr Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title_full_unstemmed Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title_short Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS
title_sort calretinin and neuropeptide y interneurons are differentially altered in the motor cortex of the sod1(g93a) mouse model of als
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353592/
https://www.ncbi.nlm.nih.gov/pubmed/28294153
http://dx.doi.org/10.1038/srep44461
work_keys_str_mv AT clarkrosemarym calretininandneuropeptideyinterneuronsaredifferentiallyalteredinthemotorcortexofthesod1g93amousemodelofals
AT blizzardcatherinea calretininandneuropeptideyinterneuronsaredifferentiallyalteredinthemotorcortexofthesod1g93amousemodelofals
AT youngkaylenem calretininandneuropeptideyinterneuronsaredifferentiallyalteredinthemotorcortexofthesod1g93amousemodelofals
AT kingannae calretininandneuropeptideyinterneuronsaredifferentiallyalteredinthemotorcortexofthesod1g93amousemodelofals
AT dicksontraceyc calretininandneuropeptideyinterneuronsaredifferentiallyalteredinthemotorcortexofthesod1g93amousemodelofals